NO913518D0 - Vaksiner for ikke typebestembar haemophilus influenzae. - Google Patents

Vaksiner for ikke typebestembar haemophilus influenzae.

Info

Publication number
NO913518D0
NO913518D0 NO913518A NO913518A NO913518D0 NO 913518 D0 NO913518 D0 NO 913518D0 NO 913518 A NO913518 A NO 913518A NO 913518 A NO913518 A NO 913518A NO 913518 D0 NO913518 D0 NO 913518D0
Authority
NO
Norway
Prior art keywords
testable
vaccines
type
extracting
haemophilus influenzae
Prior art date
Application number
NO913518A
Other languages
English (en)
Other versions
NO913518L (no
Inventor
Bruce A Green
Gary W Zlotnick
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Publication of NO913518D0 publication Critical patent/NO913518D0/no
Publication of NO913518L publication Critical patent/NO913518L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO91913518A 1989-03-09 1991-09-06 Vaksiner for ikke typebestembar haemophilus influenzae. NO913518L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09
PCT/US1990/001317 WO1990010458A1 (en) 1989-03-09 1990-03-09 Vaccines for nontypable haemophilus influenzae

Publications (2)

Publication Number Publication Date
NO913518D0 true NO913518D0 (no) 1991-09-06
NO913518L NO913518L (no) 1991-10-29

Family

ID=23248627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91913518A NO913518L (no) 1989-03-09 1991-09-06 Vaksiner for ikke typebestembar haemophilus influenzae.

Country Status (13)

Country Link
US (4) US5601831A (no)
EP (2) EP0606921B1 (no)
JP (1) JP2955014B2 (no)
KR (1) KR100188323B1 (no)
AT (2) ATE110965T1 (no)
AU (1) AU648251B2 (no)
CA (1) CA2047681C (no)
DE (2) DE69012318T2 (no)
DK (2) DK0462210T3 (no)
ES (2) ES2150450T3 (no)
FI (1) FI914241A0 (no)
NO (1) NO913518L (no)
WO (1) WO1990010458A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
AU2699192A (en) * 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
ATE190502T1 (de) * 1993-05-13 2000-04-15 American Cyanamid Co Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
ZA9810122B (en) * 1997-11-12 1999-05-12 Hoffmann La Roche Treatment of T-helper cell type 2 mediated immune diseases
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
CA2370694C (en) * 1999-06-25 2010-02-09 American Cyanamid Company Extraction of integral membrane proteins
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
EP1210114A4 (en) * 1999-08-20 2004-01-02 Gen Hospital Corp OUTER MEMBRANE PROTEIN A, PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN AND MUREINLIPOPROTEIN AS THERAPEUTIC OBJECTIVES FOR THE TREATMENT OF SEPSIS
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
CA2446355A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
JP2005508143A (ja) * 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002310760A1 (en) * 2001-06-12 2002-12-23 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2479118A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CN101180079B (zh) 2005-04-08 2012-07-18 惠氏公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
ES2557160T3 (es) * 2006-10-23 2016-01-22 Nestec S.A. Modulación del aroma y el sabor mediante biotransformación en productos lácteos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR20110111381A (ko) * 2009-01-07 2011-10-11 오츠카 세이야쿠 가부시키가이샤 전 인플루엔자균의 측정방법
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) * 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
US6420134B1 (en) 2002-07-16
US5780601A (en) 1998-07-14
DE69012318D1 (de) 1994-10-13
EP0606921B1 (en) 2000-08-02
US5601831A (en) 1997-02-11
ES2063965T3 (es) 1995-01-16
DE69033600T2 (de) 2001-04-05
CA2047681C (en) 2000-02-01
DK0462210T3 (da) 1994-10-10
JP2955014B2 (ja) 1999-10-04
CA2047681A1 (en) 1990-09-10
ATE110965T1 (de) 1994-09-15
US5955580A (en) 1999-09-21
KR100188323B1 (ko) 1999-06-01
EP0606921A1 (en) 1994-07-20
EP0462210A1 (en) 1991-12-27
DK0606921T3 (da) 2000-09-04
WO1990010458A1 (en) 1990-09-20
FI914241A0 (fi) 1991-09-09
DE69012318T2 (de) 1995-03-09
AU648251B2 (en) 1994-04-21
ATE195076T1 (de) 2000-08-15
DE69033600D1 (de) 2000-09-07
EP0462210B1 (en) 1994-09-07
AU5332690A (en) 1990-10-09
JPH07508972A (ja) 1995-10-05
NO913518L (no) 1991-10-29
ES2150450T3 (es) 2000-12-01

Similar Documents

Publication Publication Date Title
NO913518D0 (no) Vaksiner for ikke typebestembar haemophilus influenzae.
CA2069450A1 (fr) Procede de fabrication d'un materiau pour osteoplastie a partir d'un tissu osseux naturel et materiau obtenu par ce procede
YU44573B (en) Process for obtaining hypoglicemic thiazolidindione
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
NO871333D0 (no) Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
BR9608729A (pt) Preparação de um pó de proteína acilada
AU4691589A (en) Feline infectious peritonitis virus diagnostic tools
AU1141288A (en) Production of proteins in active forms
LV5765A4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
DE3861738D1 (de) Verfahren zur herstellung konzentrierter waessriger farbstoffzubereitungen.
DK498183A (da) Fremgangsmaade til fjernelse af oligomere og langsom monomer fra leukocyt-interferon (ifn-alfa)-praeparater
HUT47867A (en) Process for producing vaccine against infective peritonitis of cat
EP0271964A3 (en) Method for preparing protein hydrolysates soluble in an acid environment, and the hydrolysates obtained
FI904618A0 (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
HU892532D0 (en) Process for producing synthetic peptones and veterinary preparatives containing these compounds
JPS53127808A (en) Preparation of human albumin
DE3763312D1 (de) Verfahren zur herstellung von hexaalkyldisilan.
DK44487D0 (da) 1-oe3-(2-hydroxy-3-alkylaminopropoxy)-2-thienylaa-3-phenyl-1-propanon eller syreadditionssalt deraf samt fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende en saadan forbindelse
AU5581186A (en) Protein absorption enhancing agent
DE3067710D1 (en) Vaccine and method for its preparation
DE3264316D1 (en) Vaccine against foot-and-mouth disease and colibacillosis, and process for preparing it
ATE93725T1 (de) Pharmazeutische praeparate, die eine waesserige loesung eines pyranoquinolins enthalten.
JPS5559146A (en) Isolation of phenylalanine
EP0153171A3 (en) New 2-hydroxyethyl-trimethylammonium salt of 1-ethyl-3-carboxy-4-oxo-6,7-methylenedioxy-1,4-dihydroquinoline, process for the preparation thereof and pharmaceutical composition containing it
IL62619A (en) N,n'bis-(carboxynapthylaminocarbonylphenyl)urea derivatives,process for their preparation and method of inhibiting connective tissue destruction in animals using them